Biogen

YTD

ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,605

Employees7,605

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,605

Employees7,605

BIIB Key Statistics

Market cap

17.34B

Market cap17.34B

Price-Earnings ratio

11.69

Price-Earnings ratio11.69

Dividend yield

—

Dividend yield—

Average volume

1.56M

Average volume1.56M

High today

$119.81

High today$119.81

Low today

$115.28

Low today$115.28

Open price

$115.85

Open price$115.85

Volume

1.87M

Volume1.87M

52 Week high

$238.00

52 Week high$238.00

52 Week low

$110.04

52 Week low$110.04

BIIB News

Simply Wall St 2d

Biogen (NasdaqGS:BIIB) Selects Multiple Co-Lead Underwriters for US$1 Billion Fixed-Income Offering

appointed multiple co-lead underwriters for two fixed-income offerings totaling over $1 billion, showcasing its efforts to bolster financial offerings. This mov...

TipRanks 3d

Biogen Director Makes Strategic Stock Purchase

New insider activity at Biogen ( (BIIB) ) has taken place on May 6, 2025. Director Caroline Dorsa has made a significant investment in Biogen by purchasing 1,2...

TipRanks 4d

Biogen’s International Growth and Promising Pipeline Drive Buy Rating

Biogen (BIIB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on May 1. Analyst Marc Goodman from Leerink Partners main...

Analyst ratings

57%

of 37 ratings

Buy

43.2%

Hold

56.8%

Sell

More BIIB News

TipRanks 7d

Biogen price target lowered to $205 from $217 at RBC Capital

RBC Capital lowered the firm’s price target on Biogen (BIIB) to $205 from $217 but keeps an Outperform rating on the shares. The company’s Q1 results reaffirm t...

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.